Swantje Held

2.8k total citations
85 papers, 1.1k citations indexed

About

Swantje Held is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Swantje Held has authored 85 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Oncology, 45 papers in Pulmonary and Respiratory Medicine and 20 papers in Pathology and Forensic Medicine. Recurrent topics in Swantje Held's work include Colorectal Cancer Treatments and Studies (63 papers), Gastric Cancer Management and Outcomes (27 papers) and Hepatocellular Carcinoma Treatment and Prognosis (20 papers). Swantje Held is often cited by papers focused on Colorectal Cancer Treatments and Studies (63 papers), Gastric Cancer Management and Outcomes (27 papers) and Hepatocellular Carcinoma Treatment and Prognosis (20 papers). Swantje Held collaborates with scholars based in Germany, Austria and United States. Swantje Held's co-authors include Volker Heinemann, Dominik Paul Modest, Sebastian Stintzing, Ludwig Fischer von Weikersthal, Thomas Decker, Andreas Jung, Thomas Kirchner, Alexander Kiani, Ursula Vehling‐Kaiser and Frank Kullmann and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and The American Journal of Cardiology.

In The Last Decade

Swantje Held

79 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Swantje Held Germany	17	920	444	318	278	230	85	1.1k
Andrew Strickland Australia	12	891 1.0×	436 1.0×	278 0.9×	210 0.8×	208 0.9×	31	1.1k
Mauro D’Amico Italy	10	1.0k 1.1×	414 0.9×	284 0.9×	262 0.9×	185 0.8×	32	1.2k
Marie‐Pierre Galais France	14	784 0.9×	662 1.5×	250 0.8×	133 0.5×	434 1.9×	38	1.3k
Bum Jun Kim South Korea	18	536 0.6×	449 1.0×	145 0.5×	277 1.0×	294 1.3×	60	1.1k
Lucio Giustini Italy	20	884 1.0×	407 0.9×	294 0.9×	115 0.4×	322 1.4×	41	1.3k
Eugenio Marcuello Spain	17	1.4k 1.5×	385 0.9×	367 1.2×	227 0.8×	451 2.0×	33	1.6k
Diana L. Hanna United States	17	600 0.7×	250 0.6×	182 0.6×	117 0.4×	164 0.7×	75	1.0k
Elena Maccaroni Italy	17	545 0.6×	299 0.7×	138 0.4×	125 0.4×	101 0.4×	54	944
Alfredo Mellano Italy	12	641 0.7×	207 0.5×	135 0.4×	166 0.6×	324 1.4×	24	917
Rosella Spadi Italy	13	1.1k 1.2×	489 1.1×	193 0.6×	324 1.2×	358 1.6×	28	1.4k

Countries citing papers authored by Swantje Held

Since Specialization

Citations

This map shows the geographic impact of Swantje Held's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Swantje Held with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Swantje Held more than expected).

Fields of papers citing papers by Swantje Held

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Swantje Held. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Swantje Held. The network helps show where Swantje Held may publish in the future.

Co-authorship network of co-authors of Swantje Held

This figure shows the co-authorship network connecting the top 25 collaborators of Swantje Held. A scholar is included among the top collaborators of Swantje Held based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Swantje Held. Swantje Held is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Stahler, Arndt, Dominik Paul Modest, Sebastian Stintzing, et al.. (2024). Consensus molecular subtypes (CMS) as prognostic and predictive biomarkers of RAS wild-type (WT) metastatic colorectal cancer (mCRC): Pooled analysis of the randomized trials FIRE-1, FIRE-3, XELAVIRI, and PanaMa.. Journal of Clinical Oncology. 42(16_suppl). 3529–3529.

Stahler, Arndt, Christine Sers, Soulafa Mamlouk, et al.. (2024). Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212). Clinical Cancer Research. 30(7). 1256–1263. 9 indexed citations

Klein‐Scory, Susanne, Alexander Baraniskin, Wolff Schmiegel, et al.. (2024). Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAF V600E mutated colorectal cancer—results from the FIRE ‐4.5 study. Molecular Oncology. 19(2). 344–356. 4 indexed citations

Zhang, Danmei, C. Benedikt Westphalen, Michael Quante, et al.. (2024). Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer – Results of a phase 1b clinical trial. European Journal of Cancer. 201. 113926–113926. 5 indexed citations

Heinrich, Kathrin, Volker Heinemann, Sebastian Stintzing, et al.. (2024). Adjuvant Treatment with S-1 in Patients after R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction: A Multicenter Phase I/II Feasibility Study (GMBH-STO-0114). Oncology Research and Treatment. 47(6). 251–261. 1 indexed citations

Karthaus, Meinolf, Volker Heinemann, Jorge Riera‐Knorrenschild, et al.. (2024). Subgroup analyses from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial. BMC Cancer. 24(1). 887–887.

Dorman, Klara, Stefan Boeck, Karel Caca, et al.. (2024). Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial. The Lancet. Gastroenterology & hepatology. 9(10). 935–943. 2 indexed citations

Ballhausen, Alexej, Meinolf Karthaus, Stefan Früehauf, et al.. (2023). Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial. European Journal of Cancer. 190. 112955–112955. 5 indexed citations

Held, Swantje, R Keller, Armin Wiegering, et al.. (2023). Predictive value of computed tomography on surgical resectability in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: Results from a prospective, multicentre phase 2 trial (NEOLAP-AIO-PAK-0113). European Journal of Radiology. 163. 110834–110834. 5 indexed citations

10.

Stahler, Arndt, Dominik Paul Modest, Ludwig Fischer von Weikersthal, et al.. (2022). First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer – Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110). European Journal of Cancer. 173. 194–203. 1 indexed citations

11.

Kurreck, Annika, Alexander Beck, Uli Fehrenbach, et al.. (2022). Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212). European Journal of Cancer. 178. 37–48. 3 indexed citations

12.

Stahler, Arndt, Volker Heinemann, Kathrin Heinrich, et al.. (2021). Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial). European Journal of Cancer. 157. 71–80. 4 indexed citations

13.

Gebauer, Florian, Alexander Damanakis, Felix Popp, et al.. (2021). Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical resection in patients with hepatic Oligometastatic adenocarcinoma of the pancreas (HOLIPANC). BMC Cancer. 21(1). 1239–1239. 19 indexed citations

14.

Heinrich, Kathrin, Dominik Paul Modest, Ingrid Ricard, et al.. (2021). Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110). European Journal of Cancer. 147. 128–139. 8 indexed citations

15.

Stahler, Arndt, Sebastian Stintzing, Dominik Paul Modest, et al.. (2020). Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials. Clinical Cancer Research. 26(24). 6559–6567. 20 indexed citations

16.

Kurreck, Annika, Volker Heinemann, Ludwig Fischer von Weikersthal, et al.. (2020). Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study). European Journal of Cancer. 137. 81–92. 6 indexed citations

17.

Modest, Dominik Paul, Johann Pratschke, Hauke Lang, et al.. (2017). Central evaluation for surgical treatment options in FIRE-3- updated results and impact on overall Survival. Annals of Oncology. 28. iii148–iii149. 2 indexed citations

18.

Modest, Dominik Paul, Timm Denecke, Johann Pratschke, et al.. (2017). Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer—central evaluation of FIRE-3. European Journal of Cancer. 88. 77–86. 42 indexed citations

19.

Neumann, Ulf P., Timm Denecke, Johann Pratschke, et al.. (2016). Evaluation for surgical treatment options in metastatic colorectal cancer (mCRC) – a retrospective, central evaluation of FIRE-3. Annals of Oncology. 27. vi154–vi154. 3 indexed citations

20.

Harris, William S., et al.. (1988). The dietary risc rating a novel method to assess the hyperlipidemic potential of a diet. Arteriosclerosis An Official Journal of the American Heart Association Inc. 8(5). 633–634. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact